FENC
What one share of Fennec Pharmaceuticals holds
Biological Products, (No Diagnostic Substances)
The following is a summary of the principal risks that could adversely affect our business, operations, and financial results. A more thorough discussion of these and other risks follows this summary.
Fennec Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.77 |
|---|---|
| Profit | −$0.10 |
| Cash and investments | $1.18 |
| Debt | $0.55 |
| Book value | $1.21 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$0.22 | — | −$0.17 | — | $0.26 |
| 2017 | $0.00 | −$0.47 | — | −$0.24 | — | $1.45 |
| 2018 | $0.00 | −$0.52 | — | −$0.41 | — | $1.07 |
| 2019 | $0.00 | −$0.64 | — | −$0.46 | — | $0.60 |
| 2020 | $0.01 | −$0.76 | — | −$0.66 | — | $1.12 |
| 2021 | — | −$0.67 | — | −$0.55 | — | $0.61 |
| 2022 | $0.06 | −$0.90 | — | −$0.69 | — | −$0.10 |
| 2023 | $0.80 | −$0.60 | — | −$0.65 | — | −$0.43 |
| 2024 | $1.74 | −$0.02 | — | $0.99 | — | −$0.21 |
| 2025 | $1.56 | −$0.34 | — | −$0.44 | — | $1.04 |